ImmunoGen Inc. (NASDAQ:IMGN) announced Wednesday that itwill begin a Phase III trial of its drug Oncolysin B "soon afterthe signing of an agreement with a nationally recognizedoncology group."

The Phase III study is designed to evaluate the effectiveness ofOncolysin B in B-cell lymphoma patients who are in clinicalremission following bone marrow transplantation.

(c) 1997 American Health Consultants. All rights reserved.